Affecting a Signaling Pathway Alleviates Alzheimer’s in Mice

Key Takeaways

• SST overexpression reduces microglial activation in AD mice
• Enhanced microglial phagocytosis observed with SST treatment
• Spatial memory improves in SST‑treated 5xFAD mice
• Existing somatostatin receptor drugs could be repurposed for dementia
• SST levels are lower in human Alzheimer’s patients

Pulse Analysis

Alzheimer’s disease has long been dominated by strategies aimed at amyloid‑β and tau, yet clinical outcomes remain disappointing. Researchers are therefore turning to secondary pathways that influence neuroinflammation, a key driver of neuronal loss. Somatostatin, a neuropeptide traditionally linked to hormone regulation, is markedly depleted in the cerebrospinal fluid of Alzheimer’s patients, prompting scientists to explore its role in brain immune dynamics. By binding to somatostatin receptors on microglia, SST can potentially temper the chronic inflammatory state that fuels plaque formation and synaptic dysfunction.

In a series of experiments, the DGIST team demonstrated that SST directly enhances microglial phagocytosis and shifts cytokine expression toward an anti‑inflammatory profile. When delivered to the dentate gyrus of 5xFAD mice, SST overexpression lowered microglial density, preserved cell morphology, and, crucially, improved performance on spatial memory tasks. Early‑stage intervention yielded modest plaque reductions, whereas treatment at ten months—when plaques are well established—significantly decreased both plaque number and average size. These findings suggest that SST’s neuroprotective effects become most pronounced once amyloid pathology has progressed, offering a therapeutic window for patients with moderate disease.

The translational relevance is amplified by the existence of FDA‑approved somatostatin‑receptor agonists used for conditions such as acromegaly. Repurposing these agents could accelerate clinical testing, bypassing the lengthy safety assessments required for novel compounds. However, challenges remain, including optimal dosing, blood‑brain barrier penetration, and confirming efficacy in human microglial populations. If these hurdles are overcome, SST‑based therapies could reshape the Alzheimer’s treatment landscape, providing a disease‑modifying option that complements existing symptomatic drugs and addresses the growing demand for effective interventions.